Stem Cell Therapeutics Corp. Announces Presentations at the American Stroke Association's International Stroke Conference 2010
February 24 2010 - 8:30AM
Marketwired
Stem Cell Therapeutics Corp. ("SCT" or the "Company") (TSX VENTURE:
SSS) announced today several presentations that will be made on
behalf of SCT during the American Stroke Association's
International Stroke Conference 2010 ("ISC 2010"), February 24-26
at the Henry B. Gonzalez Convention Center in San Antonio, TX.
Drs. Steven C. Cramer of the University of California, Irvine,
CA, and Michael D. Hill of the Foothills Medical Centre at the
University of Calgary, AB, co-Principal Investigators of the Phase
IIb acute ischemic stroke trial, will be presenting the modified
REGENESIS Phase IIb protocol and study design on Wednesday.
Additionally, Dr. Ludmila Belayev of the Louisiana State
University Health Sciences Center in New Orleans, LA, will be
presenting animal stroke data with growth factors, such as human
Chorionic Gonadotropin, improving long-term outcomes when
administered the first few days after stroke.
SCT will also be hosting a Focus Group meeting on Wednesday
evening at the ISC 2010 for neurologists, clinicians, study nurses
and other attendees of the Conference to listen to presentations by
Drs. Steven C. Cramer and Michael D. Hill.
Visit Stem Cell Therapeutics at Booth No. 702 at the ISC
2010.
About the International Stroke Conference 2010;
(http://strokeconference.americanheart.org/portal/strokeconference/sc/):
The American Stroke Association, a division of the American Heart
Association, and the Stroke Council Program Committee have
established a multi-year goal to reduce death and disability from
stroke by 25 percent by the year 2010. The scientific and clinical
content presented at this Conference provides the basis for the
American Stroke Association's ongoing professional education
programs. The program emphasizes basic, clinical and translational
sciences as they evolve toward a more complete understanding of
stroke pathophysiology with the overall goal of developing more
effective prevention and treatment. The International Stroke
Conference provides unique opportunities to meet with colleagues
from around the world with wide-ranging research interests and
expertise in stroke prevention, diagnosis, treatment and
rehabilitation. Last year's professional attendance was the second
highest in the conference's history. This year, attendance is
expected to be more than 3,500 professionals, as well as exhibitors
displaying new stroke products and services.
About Stem Cell Therapeutics Corp.: Stem Cell Therapeutics Corp.
is a public biotechnology company (TSX VENTURE: SSS) focused on the
development and commercialization of drug-based therapies to treat
central nervous system diseases. SCT is a leader in the development
of therapies that utilize drugs to stimulate a patient's own
resident stem cells. The Company's programs aim to repair brain and
nerve function lost due to disease or injury. The Company's
extensive patent portfolio of owned and licensed intellectual
property supports the potential expansion into future clinical
programs in numerous neurological diseases such as traumatic brain
injury, multiple sclerosis, Huntington's disease, Alzheimer's
disease, and ALS.
These securities have not been registered under the United
States Securities Act of 1933, as amended, or the securities laws
of any state, and may not be offered or sold within the United
States or to, or for the account or benefit of U.S. persons unless
an applicable exemption from U.S. registration requirements is
available.
Except for historical information, this press release may
contain forward-looking statements, which reflect the Company's
current expectation regarding future events. These forward-looking
statements involve risk and uncertainties, which may cause but are
not limited to, changing market conditions, the successful and
timely completion of clinical studies, the establishment of
corporate alliances, the impact of competitive products and
pricing, new product development, uncertainties related to the
regulatory approval process and other risks detailed from time to
time in the Company's ongoing quarterly and annual reporting.
The TSX Venture Exchange does not accept responsibility for the
adequacy or accuracy of this release.
Contacts: Stem Cell Therapeutics Corp. Alan Moore, PhD President
and CEO (403) 245-5495 ext.224 amoore@stemcellthera.com Stem Cell
Therapeutics Corp. Chloe Douglas-Crampton Investor Relations (403)
245-5495 ext. 221 crampton@stemcellthera.com
www.stemcellthera.com
Sunvest Minerals Corp (TSXV:SSS)
Historical Stock Chart
From Jun 2024 to Jul 2024
Sunvest Minerals Corp (TSXV:SSS)
Historical Stock Chart
From Jul 2023 to Jul 2024